Healthcare
Twist Bioscience Corporation(TWST)
Live Price
Offline$87.56
+5.66% today
1Y Change
+152.77%
Window
Jun 20, 2025 โ Jun 18, 2026
- Market Cap
- $3.70B
- Revenue Growth
- +20.3%
- EPS Growth
- +63.9%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 20, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Twist Bioscience Corporation (TWST) is a Healthcare stock with a market cap of $3.70B and listed on NASDAQ. The stock last traded around $87.56 and up 152.8% across the available one-year price window (Jun 20, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +20.3%, EPS growth of +63.9%, a dividend yield of 0.0%. What stands out right now is revenue +20.3%, EPS +63.9%, free cash flow -9.3% with operating margin -34.4% and ROIC -23.6%. Valuation already assumes a fairly strong business story at price/sales 9.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TWST price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+20.3% vs +7.6% peer median
Operating Margin
Below sector median
-34.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +20.3% and EPS at +63.9%, with operating margin around -34.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.6% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | +0.9% | +0.0% | +24.8% |
2026 Feb 2, 2026 | -4.2% | -1.0% | +1.4% | -0.3% |
2025 Nov 14, 2025 | +10.0% | -1.5% | +6.3% | +15.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TWST
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TWST Max Drawdown
-38.24%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TWST and SPY.
Company Overview
Twist Bioscience Corporation
NASDAQ Global Select
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
- Leadership
- Emily Marine Leproust
- IPO Date
- Oct 31, 2018
- Employees
- 923
- Street Address
- 681 Gateway Boulevard
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 800 719 0671
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 9.5
- Price/Book
- 8.1
Growth
- Revenue
- +20.3%
- EPS
- +63.9%
- Free Cash Flow
- -9.3%
Profitability
- Gross Margin
- 51.6%
- Operating Margin
- -34.4%
- Net Margin
- -19.6%
- ROE
- -16.6%
- ROIC
- -23.6%
Balance Sheet
- Debt/Equity
- 0.40
- Current Ratio
- 3.78
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.